Crizotinib is highly effective in patients with ALK-positive NSCLC, similarly to the effects of imatinib in BCR-ABL-positive CML or of gefitinib in EGFR-mutated NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.